Addex Therapeutics Soars 24.5% on Intraday Surge: What's Fueling the Biotech's Volatility?

Summary
• Addex Therapeutics (ADXN) surges 24.5% to $10.935, hitting its 52-week high of $12.0499
• Q1 2025 cash reserves climb to CHF2.8 million, bolstered by Neurosterix transaction proceeds
• GABAB PAM chronic cough candidate shows robust preclinical anti-tussive activity
• W&H acquisition of Addex Inc. signals strategic expansion in blown film cooling tech

Today’s explosive move in Addex Therapeutics has ignited speculation about the biotech’s near-term trajectory. With a 24.5% intraday gain and a price nearing its 52-week high, the stock’s volatility contrasts sharply with a subdued biotech sector. Key catalysts include recent clinical progress in chronic cough and substance use disorder programs, alongside strategic business milestones. The surge follows a Q1 2025 report highlighting a stronger cash position and renewed focus on mGlu5 NAMs for brain injury recovery.

Clinical Progress and Strategic Acquisitions Drive Momentum
Addex Therapeutics’ 24.5% intraday rally stems from a confluence of clinical and business developments. The Q1 2025 report highlighted a CHF2.8 million cash position, driven by the Neurosterix transaction, and renewed rights to its Phase 2 mGlu2 PAM asset, ADX71149. The GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in preclinical models, while the partnership with Sinntaxis for mGlu5 NAMs in brain injury recovery adds a new therapeutic avenue. Additionally, the acquisition of Addex Inc. by W&H Corporation underscores the company’s strategic positioning in industrial technology, though this appears unrelated to the biotech’s core pipeline. These factors collectively signal a pivot toward operational efficiency and diversified revenue streams.

Technical Setup and ETF Alignment for Biotech Bulls
• 200-day average: 8.0175 (below current price)
• RSI: 51.05 (neutral)
• MACD: -0.0453 (bearish signal), Signal Line: -0.0830 (bearish divergence)
• Bollinger Bands: Price at 10.935 exceeds upper band of 8.909, indicating overbought conditions

Technical indicators suggest a short-term bullish trend, with the stock trading above its 200-day moving average and near the 52-week high. However, the RSI hovering near 50 and a bearish MACD histogram signal caution. For ETF alignment, consider the iShares Biotechnology ETF (IBB) to capitalize on sector-wide momentum. While no options data is available, a long-term hold strategy is warranted given the company’s cash position and clinical milestones. Investors should monitor the $12.0499 52-week high as a critical resistance level; a breakout could validate the bullish case.

Backtest Addex Therapeutics Stock Performance
Key take-aways:1. Six instances of ≥ 25 % intraday price spikes were identified in ADXN (2022-09-12 ~ 2025-09-12).2. A 30-day event study shows weak and negative post-spike performance: median cum. return ≈ -24 % vs S&P500 ≈ -1.8 %; win-rate falls from 50 % day-1 to 17 % day-30; no period reached statistical significance.Implication: For ADXN, chasing a 25 % “pop” has not been a profitable short-term strategy over the past four years.You can explore detailed tables/curves in the interactive panel.Let me know if you’d like to adjust the window length, add stop-loss rules, or analyse other thresholds/tickers.

Position for the Next Catalyst: Cash, Clinicals, and Strategic Synergies
Addex Therapeutics’ 24.5% surge reflects a mix of clinical progress and financial strength, but sustainability hinges on maintaining its CHF2.8 million cash runway and advancing its GABAB PAM and mGlu5 NAM programs. The biotech sector leader Amgen (AMGN) fell 2.13% today, underscoring sector-wide volatility. Investors should prioritize monitoring the Q1 2025 conference call for operational updates and the FDA’s stance on its chronic cough candidate. A breakout above $12.0499 could attract institutional buying, while a pullback to the 200-day average at $8.0175 offers a second-chance entry. Act now: Secure a position ahead of the 52-week high test or consider IBB for sector exposure.